Brainsway Ltd. requires FDA clearance for its Deep TMS protocol, tied to regional market growth in North America.
1 report, 1 independent
Updated Jul 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Brainsway Ltd. requires FDA clearance for its Deep TMS protocol, tied to regional market growth in North America.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Brainsway Ltd.
Medical technology company
Nothing else this week.
- FDA
Related events
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.
- Industry trends are influenced by regulatory body requests, according to a recent report involving RTI International.
- Market growth for bioidentical hormones is projected to reach $5.74 billion by 2031, while the FDA monitors market trends and shortages.
Coverage
Newest first; wire copies grouped- foreignpolicyjournal.comZacks Names Brainsway (NASDAQ: BWAY) Bull Of The Day While Lululemon (NASDAQ: LULU) Earns Bear Designation